The majority of elderly nursing home patients who undergo surgical or endovascular revascularization for lower-extremity PAD are unlikely to have improvements in function, and a high percentage will ...

Please provide your email address to receive an email when new articles are posted on . Patients who underwent atherectomy during endovascular lower-extremity revascularization had lower rates of ...

Preoperative statins are associated with improved limb salvage after lower extremity revascularization, either endovascular or surgical. Patients who benefit most seem to be those with claudication, ...

Patients with diabetes and symptomatic peripheral artery disease are at a higher risk for major amputation and all-cause death at 12 months after endovascular revascularization, especially among those ...

Lower extremity artery disease (LEAD) is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people. On top of that, LEAD also represents a prominent marker of ...

People who took rivaroxaban (Xarelto) after lower-extremity revascularization for peripheral artery disease (PAD) enjoyed fewer subsequent major adverse limb and cardiovascular events, according to ...

New analysis of chronic limb-threatening ischemia (CLTI) treatment outcomes was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) ...

Over 200 million people around the world experience peripheral artery disease (PAD) -- a condition caused by the narrowing of the blood vessels from the heart to the lower limbs that leads to pain ...

Patients with leg pain caused by arterial disease may be able to forgo treatment of the affected artery by participating in hospital-supervised exercise, according to a new study. Patients with leg ...

RARITAN, N.J., May 16, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO (R) (rivaroxaban) ...